Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above 200-Day Moving Average – Should You Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.30 and traded as high as $3.50. Sonoma Pharmaceuticals shares last traded at $3.10, with a volume of 811,769 shares changing hands.

Sonoma Pharmaceuticals Trading Up 10.7 %

The stock has a fifty day simple moving average of $3.12 and a two-hundred day simple moving average of $1.30. The company has a market cap of $2.98 million, a PE ratio of -0.62 and a beta of 1.38.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is owned by institutional investors and hedge funds.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.